Clinical Trial Update: S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma [Phase 2]

View source ↗

Summary

Phase 2 SWOG S1304 evaluated the combination of carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma; results from the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Dexamethamone (dexamethasone)
• Kyprolis (carfilzomib)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-06